Drugs / GLH8NDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04104997 | Sep 2019 → Feb 2020 | dry eye syndrome | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04679883 | Apr 2021 → Jan 2022 | dry eye syndrome | GL Pharm Tech Corporation | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLH8NDE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04679883 ↗ |
| Route | Topical | “5% GLH8NDE as eye drops” NCT04104997 ↗ |